>

Paul Rothman - Merck Independent Director

<div class='circular--portrait' style='background:#FF6600;color: white;font-size:3em;padding-top: 40px;;'>MRK</div>
MRK -- USA Stock  

Earning Report: 28th of April 2020  

  Director
Dr. Paul B. Rothman is Independent Director of the Company. Dr. Rothman oversees the Johns Hopkins Health System and school of medicine. A rheumatologist and molecular immunologist, he joined Johns Hopkins in July 2012 after having served as dean of the Carver College of Medicine at the University of Iowa and leader of its clinical practice plan since 2008. He previously served as head of internal medicine at the University of Iowa from 2004 until 2008. Prior to that, he was vice chairman for research and founding director of the Division of Pulmonary, Allergy and Critical Care Medicine at Columbia University College of Physicians and Surgeons, where he joined the faculty in 1986. Dr. Rothman is a 1980 Phi Beta Kappa graduate of the Massachusetts Institute of Technology and earned his medical degree from Yale University in 1984. He is a member of the American Society for Clinical Investigation and is a fellow of the American College of Physicians. He was elected to the council of Association of American Physicians as a fellow of the American Association for the Advancement of Sciences and as a member of the American Clinical and Climatological Association.
Age: 60  Director Since 2015      
908 735-1500  www.merck.com

Management Efficiency

The company has Return on Asset of 0.13 % which means that on every $100 spent on asset it made $0.13 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.39 % implying that it generated $0.39 on every 100 dollars invested.
The company has 27.59 B in debt with debt to equity (D/E) ratio of 99.4 . This implies that the company may be unable to create cash to meet all of its financial commitments. Merck has Current Ratio of 1.19 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Dennis AusielloPfizer
2015
Scott DavisJohnson Johnson
2016
Nancy AndrewsNovartis AG
2015
Dimitri AzarNovartis AG
2012
Hubert JolyJohnson Johnson
2019
Srikant DatarNovartis AG
2003
Laurie GlimcherBristol Myers Squibb Company
N/A
Carla HillsGilead Sciences
N/A
Joseph EchevarriaPfizer
2015
Urs RohnerGlaxoSmithKline PLC
2015
Ron TaylorAllergan Plc
2013
Kelly KramerGilead Sciences
2016
Ton BuechnerNovartis AG
2016
Thomas FreymanAllergan Plc
2018
John MadiganGilead Sciences
2005
Anne MulcahyJohnson Johnson
2012
Mark WeinbergerJohnson Johnson
2019
James SmithPfizer
2014
Andreas PlantaNovartis AG
2006
Marvinder BangaGlaxoSmithKline PLC
2016
Iain MackayGlaxoSmithKline PLC
2019

Company Summary

It operates through Pharmaceutical and Animal Health segments. Merck Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 71000 people.Merck Company (MRK) is traded on BATS Exchange in USA. It is located in 2000 Galloping Hill Road, Kenilworth, NJ 07033, United States and employs 71,000 people. Merck Company was previously known as Merck Co and was traded on BATS Exchange under the symbol SGP. Merck is listed under Pharmaceutical Products category by Fama And French industry classification.

Merck Leadership Team

Thomas Glocer, Independent DirectorView
Craig Thompson, Independent DirectorView
Jennifer Zachary, Executive Vice President, General CounselView
Rochelle Lazarus, Independent DirectorView
Christine Seidman, DirectorView
Michael Rosenblatt, Executive Vice President Chief Medical OfficerView
Wendell Weeks, Independent DirectorView
Michael Holston, Executive Vice President Chief Ethics and Compliance OfficerView
Kathy Warden, DirectorView
Paul Rothman, Independent DirectorView
Mary Coe, Independent DirectorView
Adele Ambrose, Senior Vice President Chief Communications OfficerView
Joseph Romanelli, IR Contact OfficerView
Mirian GraddickWeir, Executive Vice President - Human ResourcesView
Peter Wendell, Independent DirectorView
John Noseworthy, Independent DirectorView
Leslie Brun, Lead Independent DirectorView
Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population HealthView
Inge Thulin, Independent DirectorView
Pamela Craig, Independent DirectorView
Patricia Russo, Independent DirectorView
Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing DivisionView
Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global ControllerView
Robert Davis, Executive Vice President, Global Services, Chief Financial OfficerView
Robert Kidder, Independent DirectorView
Thomas Cech, Independent DirectorView
Michael Nally, Executive Vice President, Chief Marketing OfficerView
Clark Golestani, CIO and Executive VPView
William Harrison, Lead Independent DirectorView
Roger Perlmutter, Executive Vice President and Presidentident - Merck Research LaboratoriesView
Ashley Watson, Senior Vice President Chief Ethics and Compliance OfficerView
Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human ResourcesView
Jim Scholefield, Executive Vice President, Chief Information and Digital OfficerView
Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing DivisionView
Adam Schechter, President of Global Human Health and Executive VPView
Carlos Represas, Independent DirectorView
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal HealthView
Kenneth Frazier, Chairman of the Board, President, Chief Executive OfficerView
Frank Clyburn, Executive Vice President, Chief Commercial OfficerView

Stock Performance Indicators

Did you try this?

Run Stock Screener Now

   

Stock Screener

Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Please also try Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page